Asset profile

Sacituzumab Govitecan

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved — HR+/HER2- Metastatic Breast Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(53 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (8)

September 2026 (1)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-09 · NCT05186974 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (1)

Phase 3Triple Negative Breast Cancer, Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-10-01 · NCT05552001 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-11-01 · NCT06401824 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (5)

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12 · NCT04639986 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNARecruiting

Est. primary completion 2026-12-30 · NCT04434040 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting

Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerEnrolling by invitation

Est. primary completion 2026-12-31 · NCT07359404 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-31 · NCT05675579 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (25)

January 2027 (6)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-01 · NCT06827613 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-01 · NCT04039230 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-01-12 · NCT05609968 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Leptomeningeal MetastasesRecruiting

Est. primary completion 2027-01-15 · NCT06462092 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Brain MetastasisNot yet recruiting

Est. primary completion 2027-01-15 · NCT06462079 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer …Active not recruiting

Est. primary completion 2027-01-31 · NCT03971409 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (4)

Phase 1/2Breast Cancer, Triple Negative Breast CancerRecruiting

Est. primary completion 2027-02 · NCT06238921 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-02 · NCT06612203 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Triple Negative Breast Cancer, PD-L1 PositiveActive not recruiting

Est. primary completion 2027-02 · NCT05382286 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-02-28 · NCT07438600 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)

Phase 3HER2-negative Breast Cancer, Triple Negative Breast CancerActive not recruiting

Est. primary completion 2027-03-30 · NCT04595565 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, Triple Negative Breast Cancer, PD-L1 NegativeRecruiting

Est. primary completion 2027-04-01 · NCT04468061 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-05 · NCT05101096 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-05-01 · NCT06665178 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (6)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-06 · NCT07367178 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple Negative Breast NeoplasmsNot yet recruiting

Est. primary completion 2027-06 · NCT07040644 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Triple Negative Breast CancerRecruiting

Est. primary completion 2027-06 · NCT05633654 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-06-01 · NCT07368543 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast CancerRecruiting

Est. primary completion 2027-06-30 · NCT06878625 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-06-30 · NCT06616987 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 2Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast CancerNot yet recruiting

Est. primary completion 2027-08 · NCT07299409 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-11-01 · NCT06667167 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-12-31 · NCT05601440 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-12-31 · NCT04647916 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (12)

January 2028 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-03-11 · NCT07471776 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2028-04 · NCT05840211 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (3)

Phase 1/2Triple Negative Breast CancerRecruiting

Est. primary completion 2028-06 · NCT06926920 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-06 · NCT06263543 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-06-01 · NCT04986579 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (2)

Phase 3Triple Negative Breast Cancer, PD-L1 NegativeActive not recruiting

Est. primary completion 2028-07 · NCT05382299 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Metastatic Triple-Negative Breast CancerRecruiting

Est. primary completion 2028-07-01 · NCT07011654 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)

Phase 2Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting

Est. primary completion 2028-08-01 · NCT05770531 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)

Phase 2Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast CancerRecruiting

Est. primary completion 2028-10 · NCT04230109 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)

Phase 2Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Not yet recruiting

Est. primary completion 2028-11-30 · NCT07393555 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (1)

Phase 2Lung CancerActive not recruiting

Est. primary completion 2028-12-30 · NCT06055465 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (3)

September 2029 (2)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2029-09 · NCT05633667 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Triple Negative Breast CancerRecruiting

Est. primary completion 2029-09 · NCT06081244 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2029 (1)

Phase 2Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast CancerNot yet recruiting

Est. primary completion 2029-10 · NCT07151586 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (3)

March 2030 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)

Phase 1/2Metastatic Triple-negative Breast CancerRecruiting

Est. primary completion 2030-12 · NCT06963905 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)

November 2031 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2031-11-30 · NCT06431633 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (1)

March 2033 (1)

Phase 3Breast Cancer, Triple-negative Breast CancerNot yet recruiting

Est. primary completion 2033-03-31 · NCT07178730 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.